Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.
2 reports, 1 independent
Updated Jul 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
-
MarketBeat
American personal finance blog
Related events
- Royal Bank of Canada issued a price objective and Benzinga reported a target price reduction for Aardvark Therapeutics, Inc.
- MarketBeat is providing average rating data as Royal Bank of Canada issues a price target report regarding ConocoPhillips.
- Financial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.
- Royal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.
- Royal Bank of Canada reiterated a sector perform rating for Lucid Group, Inc., with MarketBeat providing average rating and price target.